Retraction: Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era (PLoS ONE 8: 2 (e55717) DOI: 10.1371/journal.pone.0055717);Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Iqbal, Zafar ^a,i,l,o   Aleem, Aamer ^b   Iqbal, Mudassar ^c,o   Naqvi, Mubashar Iqbal ^d,o   Gill, Ammara ^e,o   Taj, Abid Sohail ^f   Qayyum, Abdul ^g   ur Rehman, Najeeb ^h   Khalid, Ahmad Mukhtar ⁱ   Shah, Ijaz Hussain ^j   Khalid, Muhammad ^j   Haq, Riazul ^k,l   Khan, Mahwish ^l,o   Baig, Shahid Mahmood ^m   Jamil, Abid ⁿ   Abbas, Muhammad Naeem ^o   Absar, Muhammad ^o   Mahmood, Amer ^p   Rasool, Mahmood ^q   Akhtar, Tanveer ^o  

^a KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER   (Saudi Arabia)

^b KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^c Foreign Faculty   (Kyrgyzstan)

^d Government Elementary School Chak 19 SB   (Pakistan)

^e Institute of Radiotherapy and Nuclear Medicine ^*

^f University Campus   (Pakistan)

^g PAKISTAN INSTITUTE OF MEDICAL SCIENCES   (Pakistan)

^h University of Sargodha   (Pakistan)

ⁱ UNIVERSITY OF SARGODHA   (Pakistan)

^j PUNJAB MEDICAL COLLEGE   (Pakistan)

^k UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^l UNIVERSITY OF LAHORE   (Pakistan)

^m NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

ⁿ Hayatabad Medical Complex Hospital   (Pakistan)

^o UNIVERSITY OF THE PUNJAB   (Pakistan)

^p KING SAUD UNIVERSITY   (Saudi Arabia)

^q KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BCR ABL PROTEIN; CD34 ANTIGEN; CYTOSINE; GUANINE; IMATINIB; THYMINE;

ADOLESCENT; ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BCR ABL GENE; CD34 SELECTION; CELL ISOLATION; CHILD; CHRONIC MYELOID LEUKEMIA; DRUG DOSE ESCALATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PERSONALIZED MEDICINE; PROTEIN DOMAIN; SCHOOL CHILD; SEQUENCE ANALYSIS;

EID: 84873648419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0301946     Document Type: Erratum

References (46)

1. Goldman JM, Melo JV, (2003) Mechanisms of Disease: Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 349: 1451-1464.
2. Goldman JM, (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood 110: 2828-2837.
3. Kantarjian H, Cortes J (2008) BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. J Natl Compr Canc Netw Suppl 2: S37-S42; quiz S43-S44.
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
5. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, et al. (2006) GIMEMA Working Party on Chronic Myeloid Leukemia. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12: 7374-7379.
6. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
7. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, et al. (2003) Dose escalation of Imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101: 473-475.
8. Barańska M, Lewandowski K, Gniot M, Iwoła M, Lewandowska M, et al. (2008) Komarnicki M. Dasatinib treatment can overcome imatinib and nilotinib resistance in a CML patient carrying F359I mutation of BCR-ABL oncogene. J Appl Genet 49: 201-203.
9. Cortes J, Kantarjian H, (2008) Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. J Natl Compr Canc Netw 6Suppl 2: S22-S30.
10. Nicolini FE, Corm S, Lê QH, Sorel N, Hayette S, et al. (2006) Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 20: 1061-1066.
11. Apperley JF, (2007) Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8: 1018-1029.
12. Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, et al. (2007) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 110: 727-734.
13. Soverini S, Vitale A, Poerio A, Gnani A, Colarossi S, et al. (2011) Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 96: 552-557.
14. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Laï JL, Philippe N, et al. (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100: 1014-1018.
15. Roche-Lestienne C, Laï JL, Darré S, Facon T, Preudhomme C, (2003) A mutation conferring resistance to Imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med 348: 2265-2266.
16. Kreuzer KA, Le Coutre P, Landt O, Na IK, Schwarz M, et al. (2003) Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol 82: 284-289.
17. Carella AM, Garuti A, Cirmena G, Catania G, Rocco I, et al. (2010) Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. Leuk Lymphoma 5: 275-278.
18. Willis SG, Lange T, Demehri S, Otto S, Crossman L, et al. (2005) High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106: 2128-2137.
19. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, et al. (2005) Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105: 2093-2098.
20. Jiang X, Forrest D, Nicolini F, Turhan A, Guilhot J, et al. (2010) Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood 116: 2112-2121.
21. Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, et al. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99: 319-325.
22. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, et al. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 107: 4532-4539.
23. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, et al. (2007) Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21: 926-935.
24. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, et al. (2006) European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108: 1809-1820.
25. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, et al. (2004) Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104: 2926-2932.
26. Holyoake TL, Jiang X, Jorgensen HG, Graham S, Alcorn MJ, et al. (2001) Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 97: 720-728.
27. Hao QL, Smogorzewska EM, Barsky LW, Crooks GM, (1998) In vitro identification of single CD34+CD38- cells with both lymphoid and myeloid potential. Blood 91: 4145-4151.
28. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, et al. (1995) Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 85: 2632-2638.
29. Kang HY, Hwang JY, Kim SH, Goh HG, Kim M, et al. (2006) Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica 91: 659-662.
30. Iqbal Z, Siddique RT, Qureshi JA, Khalid AM, (2004) Case study of primary imatinib resistance and correlation of BCR-ABL multiple mutations in chronic myeloid leukemia. Therapy 1: 249-254.
31. Wongboonma W, Thongnoppakhun W, Auewarakul CU, (2012) BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and-exposed Southeast Asian chronic myeloid leukemia patients. Exp Mol Pathol 92: 259-265.
32. Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, et al. (2011) Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118: 5565-5572.
33. Leder K, Foo J, Skaggs B, Gorre M, Sawyers CL, et al. (2011) Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One 6: e27682.
34. Branford S, Hughes T, (2006) Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med125: 93-106.
35. Jiang X, Saw KM, Eaves A, Eaves C, (2007) Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 99: 680-693.
36. Sorel N, Bonnet ML, Guillier M, Guilhot F, Brizard A, et al. (2004) AG. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun 323: 728-730.
37. Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, et al. (2008) Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.J Clin Oncol. 26: 4806-4813.
38. O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, (2011) et al. NCCN Task Force Report: Tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 9: S1-S25.
39. Hughes T, Saglio G, Branford S, Soverini S, Kim DW, et al. (2009) Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 27: 4204-4210.
40. Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, et al. (2007) Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 21: 489-493.
41. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16: 401-412.
42. Dolgin E (2013) As leukemia options grow, drugs jockey to be first-line therapies. Nature Medicine 19, 7-7; doi: 10.1038/nm0113-7.
43. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, et al. (2008) Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83: 258-264.
44. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, et al. (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112: 2024-2027.
45. Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, et al. (2008) A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 22: 1963-1966.
46. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, et al. (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28: 2381-2388.